Sangdunchoi:company

From OpenWetWare
Jump to navigationJump to search
Snk logo.png



Snk-fig-slash.png S&K Therapeutics

We will provide patients with better life opportunities by developing therapeutic agents for immune diseases.


AI drug development.png




Snk-fig-slash.png About snktherapeutics.com

Snk-fig-1.png

S&K Therapeutics owns an AI-based drug development platform that allows us to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors), S&K therapeutics is establishing new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases.

Snk-fig-slash.png Vision

S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicine for lupus, RA, psoriasis, Alzheimer's, and diabetes.

Plarform Technology Snk-fig-platform-technology.png

Artificial Intelligence for Development of New Drugs

Solid Basic Research & Development Snk-fig-solid r&d.png

TLR Target New Drug Discovery-POC Study, MOA Study

Global License Out Snk-fig-license-out.png

Open Innovation & Technology IP Transfer

CEO

Snk-fig-ceo.png

Career

  • Dean of College of Natural Sciences, Ajou University, Korea (2018 ~ present)
  • Adjunct Professor in Rheumatology Department, Ajou University Medical School (2015 ~ present)
  • Professor in Dept. of Molecular and Science and Technology, Ajou University (2006 ~ present)
  • Transcriptome Analysis Lab Director, California Institute of Technology, USA (1997-2006)

Platform Technology

Snk-fig-platform-technology-flow.png

S&K is a new drug development platform that mainly focuses on the lead compound discovery using artificial intelligence and computational techniques. S&K implements the innovative technology that can reduce the total duration of drug development from 10 years to 5 years.

Target

Snk-fig-pathways.png

The TLR (Toll-like receptor) is one of the major factors in the pathogenesis of lupus. TLR signaling pathway plays a crucial role in the activation of innate immune responses, which is the first line of defense against external/foreign substances. TLR immediately responds to the invading pathogenic substances and secretes various cytokines to help the development of acquired immunity. However, if TLR signaling is over-activated, it can cause autoimmune or inflammatory diseases such as systemic lupus erythematosus or rheumatoid arthritis, which can be treated by directly blocking the signal transduction of the TLR.

Snk-fig-slash.png R&D

INDICATION

Lupus is a disease that causes inflammatory reactions due to autoimmunity, which has various symptoms such as skin rash, photosensitivity, arthritis, canker sores, nephritis, hematocytopenia, angitis and hydrohymenitis.

Snk-fig-indication.png


LUPUS

The reduction of lupus markers and inflammatory cytokines in lupus animal models.

Snk-fig-lupus.png


RHEUMATOID ARTHRITIS

Reduction of RA indicators in the animal model and confirmation of the effect in tissue and joint recovery.

Snk-fig-rheumatoid-arthritis.png


PIPELINE
  • Six new drug pipelines (SLE) and 2 new drug candidates (RA) in the progress of optimizing
  • Completion of patent applications (Korean Intellectual Property Office) & PCT applications


Snk-fig-pipeline.png

Snk-fig-slash.png S&K News

Snk-fig-khidi.png

Korean researchers have made great progress in developing treatments for autoimmune and inflammatory diseases.

Snk-fig-nrf.png

When will the systemic lupus erythematosus cure come out?

Snk-fig-slash.png Notice

Snk-fig-slash.png Contact

Snk-fig-contact.png

Woncheon hall 136, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea

Tel : +82 10 9098 3629

e-mail : yunsangyong@gmail.com


We will provide patients with better life opportunities by developing therapeutic agents for immune diseases.